Insider Transactions in Q1 2024 at Exact Sciences Corp (EXAS)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
2,000
-2.64%
|
$140,000
$70.0 P/Share
|
|
Mar 01
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,412
-18.07%
|
$142,308
$59.32 P/Share
|
|
Mar 01
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
862
-8.63%
|
$50,858
$59.32 P/Share
|
|
Mar 01
2024
|
Daniel J Levangie |
SELL
Open market or private sale
|
Direct |
5,000
-17.87%
|
$285,000
$57.5 P/Share
|
|
Mar 01
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
2,154
-13.07%
|
$127,086
$59.32 P/Share
|
|
Mar 01
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
2,323
-14.15%
|
$137,057
$59.32 P/Share
|
|
Mar 01
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,724
-2.22%
|
$101,716
$59.32 P/Share
|
|
Mar 01
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
8,271
-0.63%
|
$487,989
$59.32 P/Share
|
|
Mar 01
2024
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,412
-4.96%
|
$142,308
$59.32 P/Share
|
|
Mar 01
2024
|
James Edward Doyle |
SELL
Open market or private sale
|
Direct |
2,000
-3.84%
|
$114,000
$57.5 P/Share
|
|
Feb 29
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,291
+28.39%
|
-
|
|
Feb 29
2024
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
1,890
+15.91%
|
-
|
|
Feb 29
2024
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
4,724
+22.28%
|
-
|
|
Feb 29
2024
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
4,724
+22.34%
|
-
|
|
Feb 29
2024
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
3,779
+4.65%
|
-
|
|
Feb 29
2024
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,143
+1.37%
|
-
|
|
Feb 29
2024
|
Everett Cunningham Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,291
+9.82%
|
-
|
|
Feb 27
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
2,027
-14.77%
|
$113,512
$56.89 P/Share
|
|
Feb 27
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,880
-2.49%
|
$105,280
$56.89 P/Share
|
|
Feb 27
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
6,263
-0.48%
|
$350,728
$56.89 P/Share
|
|
Feb 27
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,710
-25.18%
|
$151,760
$56.89 P/Share
|
|
Feb 27
2024
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,648
-7.77%
|
$204,288
$56.89 P/Share
|
|
Feb 27
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
784
-8.83%
|
$43,904
$56.89 P/Share
|
|
Feb 27
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
1,879
-13.78%
|
$105,224
$56.89 P/Share
|
|
Feb 26
2024
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+22.37%
|
-
|
|
Feb 26
2024
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+4.97%
|
-
|
|
Feb 26
2024
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,181
+1.01%
|
-
|
|
Feb 26
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,701
+34.63%
|
-
|
|
Feb 26
2024
|
Everett Cunningham Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,678
+14.06%
|
-
|
|
Feb 26
2024
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
1,648
+15.65%
|
-
|
|
Feb 26
2024
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+22.48%
|
-
|
|
Feb 23
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,021
-1.4%
|
$60,239
$59.72 P/Share
|
|
Feb 23
2024
|
Kevin T Conroy President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
61,560
-4.58%
|
$3,508,920
$57.53 P/Share
|
|
Feb 23
2024
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
102,837
+7.11%
|
$1,336,881
$13.96 P/Share
|
|
Feb 22
2024
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
663
-1.47%
|
$39,117
$59.78 P/Share
|
|
Feb 22
2024
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,350
-3.32%
|
$79,650
$59.78 P/Share
|
|
Feb 22
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,351
-21.06%
|
$79,709
$59.78 P/Share
|
|
Feb 22
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
291
-3.87%
|
$17,169
$59.78 P/Share
|
|
Feb 22
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
1,013
-9.47%
|
$59,767
$59.78 P/Share
|
|
Feb 22
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
1,093
-10.06%
|
$64,487
$59.78 P/Share
|
|
Feb 22
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,013
-1.37%
|
$59,767
$59.78 P/Share
|
|
Feb 22
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
11,565
-0.92%
|
$682,335
$59.78 P/Share
|
|
Feb 21
2024
|
D Scott Coward |
BUY
Grant, award, or other acquisition
|
Direct |
2,034
+4.31%
|
-
|
|
Feb 21
2024
|
Everett Cunningham Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,711
+6.26%
|
-
|
|
Feb 21
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,711
+29.71%
|
-
|
|
Feb 21
2024
|
James Herriott SVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
581
+7.17%
|
-
|
|
Feb 21
2024
|
Jacob A Orville EVP, GM, Screening |
BUY
Grant, award, or other acquisition
|
Direct |
2,034
+15.98%
|
-
|
|
Feb 21
2024
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
2,034
+15.77%
|
-
|
|
Feb 21
2024
|
Sarah Condella EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
2,034
+2.69%
|
-
|
|
Feb 21
2024
|
Kevin T Conroy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,238
+1.82%
|
-
|